Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Advocacy » ENETS session – High grade classification

ENETS session – High grade classification

  • March 26, 2019

(by Meredith Cummins, NSW Project Officer)

The 16th ENETs Conference for the Diagnosis and Treatment of Neuroendocrine Tumour Disease was a wonderful opportunity to network internationally and gain knowledge and insight into the great work being done in this field. There were so many fabulous sessions, so many that it was difficult to report on them all. The session below was part of the ENETs / European Society of Pathology (ESP) New Classification / Making Sense of High-grade Neoplasms. Within this session Dr Jean – Yves Scoazec from France presented Pulmonary and Digestive High Grade NENs – Where are they similar? The following highlights the grading and a conclusion of the grading. So much work is being done to better define the respective NETs so that treatment can be customized for better management.

WHO classification of digestive NENs (2019) is divided into-

  • Neuroendocrine tumour G1 – differentiation  – well differentiated, mitotic index ,2 mitoses / 2mm2, Ki 67 Index <= 2% (Low Grade)
  • Neuroendocrine tumour G2 – differentiation – well differentiated ,mitotic index 2-20 mitoses / 2mm2, Ki 67 Index – 3-20 % (Intermediate Grade)
  • Neuroendocrine G3 – differentiation – well differentiated, mitotic index  20 mitoses / 2 mm2, Ki 67 index >20% (High Grade)
  •  Large Cell neuroendocrine carcinoma – differentiation – poorly differentiated, mitotic index 20 mitoses / 2mm2, Ki 67 index >20% (High to very High Grade)
  • Small cell neuroendocrine carcinoma – differentiation  – poorly differentiated, mitotic index 20 mitoses / 2mm2, Ki 67 index  > 20% (High to very High Grade)

Next WHO classification of Lung NENs (20..)

  • Typical Carcinoid – differentiation  – well differentiated, necrosis  – absent, Mitotic index , 2 mitoses / 10HPF (2mm2)( Low Grade)
  • Atypical carcinoid – well differentiated, necrosis – possible, focal, mitotic index – 2-10 mitoses / 10HPF (2mm2) (Intermediate Grade)
  • Supracarcinoid – differentiation – well differentiated – (High Grade)
  • Large Cell neuroendocrine carcinoma – differentiation – poorly differentiated, necrosis – frequent, extensive, mitotic index  >10mitoses/ 10HPF (2mm2) – (High to very High Grade)
  • Small Cell neuroendocrine carcinoma – differentiation  – poorly differentiated, necrosis  – frequent, extensive, mitotic index > 10 mitoses / 10HPF (2mm2) – (High to very High Grade)

So in conclusion :

  • Lung and digestive high grade NENs share some similarities but they also express site specific feature
  • High grade NETs exist in both the digestive system and the lung: they require an accurate diagnosis and probably, an adapted treatment
  • Small Cell neuroendocrine carcinoma is a distinctive entity
  • Large Cell neuroendocrine carcinoma is a diverse category with a need for a reevaluation of our diagnostic and therapeutic approaches

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousPetition update
NextLet’s BE FAIR with government cancer fundingNext

Related Posts

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

NeuroEndocrine Cancer Australia (NECA) is proud to be the voice for thousands of Australians living with Neuroendocrine Cancer (NETs). But to do more — reach

Parliament House representation for Federal Budget briefings

NECA attends the Treasurer’s Speech at Parliament House and then Medicines Australia Patient Organisation Brief at the Press Club on Wednesday 26 March 2025. The

VHL in the news March 2025

Read the Magazine copy here.

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin